Table 2.
Patients who developed hepatocellular carcinoma.
Patient | Sex | Race | Age, y | Interval between biopsy and HCC diagnosis, mo | Ishak | NAS | HAI | HBV DNA, log copies/mL |
---|---|---|---|---|---|---|---|---|
1 | Male | Malay | 51 | 114.1 | 1 | 5 | 3 | 3.6 |
2 | Male | Chinese | 42 | 128.1 | 1 | 3 | 5 | 6.0 |
3 | Male | Chinese | 26 | 139.1 | 3 | 3 | 9 | 6.0 |
4 | Male | Chinese | 45 | 129.1 | 6 | 5 | — | 6.0 |
5 | Female | Chinese | 59 | 35.0 | 5 | 7 | 8 | 6.0 |
6 | Male | Chinese | 58 | 35.0 | 5 | 3 | 7 | 6.0 |
7 | Male | Chinese | 62 | 39.0 | 3 | 2 | 5 | 6.0 |
8 | Male | Chinese | 56 | 9.0 | 2 | 6 | 6 | 6.0 |
9 | Male | Chinese | 50 | 3.0 | 0 | 0 | 3 | 6.0 |
10 | Male | Chinese | 62 | 18.0 | 3 | 2 | 4 | 6.1 |
11 | Male | Chinese | 52 | 67.1 | 3 | 5 | 3 | 6.5 |
12 | Male | Chinese | 67 | 54.0 | 1 | 2 | 5 | 6.5 |
13 | Male | Malay | 66 | 87.0 | 4 | 2 | 8 | 6.6 |
14 | Male | Chinese | 48 | 187.1 | 6 | 3 | 7 | 7.0 |
15 | Male | Chinese | 63 | 36.0 | 5 | 0 | 7 | 7.0 |
16 | Female | Malay | 46 | 74.1 | 2 | 0 | 4 | 7.1 |
17 | Male | Chinese | 44 | 87.1 | 3 | 3 | 8 | 7.7 |
18 | Female | Chinese | 68 | 91.0 | 3 | 0 | 6 | 7.9 |
19 | Female | Chinese | 55 | 131.2 | 1 | 3 | 5 | 7.9 |
20 | Female | Chinese | 62 | 53.0 | 6 | 4 | 4 | 7.9 |
21 | Male | Chinese | 73 | 89.1 | 6 | 0 | 11 | 8.4 |
22 | Male | Chinese | 36 | 115.1 | 1 | 3 | 5 | 8.6 |
23 | Female | Chinese | 68 | 137.1 | 5 | 5 | 9 | 8.7 |
24 | Male | Chinese | 44 | 158.1 | 0 | 3 | 4 | 9.0 |
25 | Male | Chinese | 52 | 50.0 | 4 | 5 | 14 | 9.0 |
26 | Male | Chinese | 39 | 114.0 | 3 | 4 | 14 | 9.0 |
27 | Male | Chinese | 59 | 46.0 | 5 | 0 | 14 | 9.0 |
Abbreviations: HAI, Hepatic Activity Index; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NAS, Non-Alcoholic Steatohepatitis Activity Score.